REFERENCES


38. Schmidt GMJ, Topochemistry. Part III. The crystal chemistry of some trans-
40. Desiraju GR, Supramolecular synthons in crystal engineering — a new organic-
41. Allen FH, The Cambridge structural database: a quarter of a million crystal
42. Bruno IJ, Cole JC, Edgington PR, Kessler MK, Macrae CF, McCabe P, New
software for searching the Cambridge structural database and visualising crystal
43. Cabrerra N, Vermilea DA, Growth Perfection of Crystals, Chapman and Hall,
London, 1958; 393.
44. Burton WK, Cabrera N, Frank FC, The growth of crystals, Philos. Trans. R. Soc,
1951; 243: 299–358.
45. Kato Y, Okamoto Y, Nagasawa S, Ishihara I, Relationship between
polymorphism and bioavailability of drug. IV. New polymorphic forms of
46. Salole EG, Al-Sarraj FA, Spiranolactone crystal forms, Drug Dev. Ind. Pharm,
47. Kobayashi Y, Ito S, Itai S, Yamamoto K, Physicochemical properties and
bioavailability of carbamazepine polymorphs and dihydrate, Int. J. Pharm, 2000;
193: 137–146.


81. Gupta VK, Jayaswal SB, Srivastava AK, Kumar MV, Controlled release microspheres of diclofenac sodium prepared by spherical crystallization technique, Pharmazie, 1994; 49: 692-693.


91. Tong HHY, Chow AHL, Control of physical forms of drug particles for pulmonary delivery by spray drying and supercritical fluid processing. KONA, 2006; 24:27–40.


137. http://serc.carleton.edu/research/education/geochemsheets/techniques/SEM.html


158. USP24/NF19, Rockvill; United State Pharmacopoeial Convention 1999.


166. Venkadari RG, Srinivas M, Madhobhai M, Patel Vice-Chancellor, Girish KJ, Department of Pharmaceutics, N. E. T. Pharmacy College, Navodaya Nagar, Mantralayam Road Raichur-584103, India.


178. ICH Topic Q3C (R5) Impurities: Guideline for Residual Solvents.


202. Japan pharmacopeia, XIV, Mefenamic acid, official monograph for part I.


205. Indian pharmacopoeia 2010 volumeII page no 1542.


221. Indian pharmacopoeia, Controller of publication, New Delhi, 2010 volume III, 1926-1927